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ABSTRACT 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. TG 
accumulation in liver is a hallmark of NAFLD. Metabolic studies have confirmed that increased 
hepatic de novo lipogenesis in humans contributes to fat accumulation in the liver and to NAFLD 
progression. Mice deficient in carboxylesterase 1d (Ces1d) expression are protected from high-fat 
diet-induced hepatic steatosis. To investigate whether loss of Ces1d can also mitigate steatosis 
induced by over-activated de novo lipogenesis, wild type and Ces1d deficient mice were fed a 
lipogenic high-sucrose diet. We found that Ces1d deficient mice were protected from high-
sucrose diet-induced hepatic lipid accumulation. Mechanistically, Ces1d deficiency leads to 
activation of AMP-activated protein kinase and inhibitory phosphorylation of acetyl-CoA 
carboxylase. Together with our previous demonstration that Ces1d deficiency attenuated high-fat 
diet-induced steatosis, this study suggests that inhibition of CES1 (the human ortholog of Ces1d) 
might represent a novel pharmacological target for prevention and treatment of NAFLD. 
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INTRODUCTION 
 
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disorder that is increasing in 
prevalence with the global epidemic of obesity in adults and children (1, 2). Hepatic steatosis 
results from an imbalance between import, synthesis, utilization, and/or export of lipids. 
Considerable evidence supports the ability of high carbohydrate diets to upregulate hepatic de 
novo lipogenesis (DNL), leading to increased triacylglycerol (TG) production (3). Over-
consumption of simple carbohydrates in processed foods and beverages, especially fructose and 
sucrose, has been implicated in NAFLD development (4, 5). Metabolites generated during 
carbohydrate metabolism in the liver serve as substrates for DNL and activate the master 
transcription factor carbohydrate-responsive element-binding protein (ChREBP) to induce mRNA 
expression of lipogenic genes, including genes encoding fatty acid synthase (FAS) and stearoyl-
CoA desaturase 1 (SCD1) (6).  
Our laboratory has investigated the role of carboxylesterases in lipid metabolism, including 
murine carboxylesterase 1d (Ces1d) [previously annotated as carboxylesterase 3 (Ces3) and 
triacylglycerol hydrolase (TGH)] (7-9). Ces1d was shown to participate in basal lipolysis in 
adipocytes (10, 11). In the liver, experimental evidence suggests that murine Ces1d and its human 
ortholog CES1 participate in the mobilization of preformed TG for very low-density lipoprotein 
(VLDL) assembly (12-15). Loss of Ces1d enhances insulin sensitivity and protects from high-fat 
diet-induced liver steatosis by increasing fatty acid (FA) oxidation and decreasing hepatic de novo 
lipogenesis (16). To specifically investigate whether ablation of Ces1d expression can alleviate 
steatosis induced by over-activated lipogenesis, we challenged Ces1d deficient mice with a high-
sucrose diet. Here we show that Ces1d deficiency protects against high-carbohydrate-induced 
liver lipid accumulation by inhibiting the key lipogenic enzyme acetyl-CoA carboxylase (ACC). 
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Animal care and diet studies 
All animal procedures were conducted in compliance with protocols approved by the University 
of Alberta’s Animal Care and Use Committee and in accordance with the Canadian Council on 
Animal Care policies and regulations. Sixteen weeks old male Ces1d deficient mice (Ces1d-/-) and 
wild-type (WT) mice of C57BL/6J background were used in the experiments (16). WT and 
Ces1d-/- mice were maintained on a 12-hour light (7 am - 7 pm)/12-hour dark (7 pm - 7 am) cycle, 
controlled for temperature and humidity and were fed either a chow diet (5% fat and 0.02% 
cholesterol PicoLab laboratory Rodent Diet 5L0D) or a high-sucrose diet (HSD, no. 901683; 74% 
kcal from sucrose, fat-free, MP Biomedical, USA, supplemental Table S1) for 8 weeks. Blood 
and tissues were collected after 16 hours fasting or after 16 hours fasting followed by 6 hours re-
feeding.  
Metabolic measurements 
Energy expenditure and fuel oxidation were assessed using the Oxymax CLAMS (Columbus 
Instruments USA). Mice were acclimated in individual chambers for one day before data 
recording. Measurements of in vivo oxygen consumption and carbon dioxide production were 
performed every 14 min over 2 days and used to calculate the respiratory exchange ratio (RER). 
Food intake was monitored during the procedure. 
Body composition measurements 
Whole body lean and fat masses were determined in mice by an EchoMRI™ system (USA) 
before and after 8 weeks of HSD feeding. 
Plasma and liver chemistries 
Enzymatic assays kits were used to measure plasma levels of free fatty acids (FFA), TG and 
ketone bodies (Wako, Japan) according to manufacturer’s instructions. Plasma insulin 
concentration was determined using the Multiplexing LASER Bead Assay (Eve Technologies, 
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chromatography (GC) as previously described (17). Hepatic fatty acid composition and 
concentration were determined by GC analysis following transesterification of fatty acids present 
in total liver lipid extract to fatty acid methyl esters in the presence of 17C-fatty acid as an 
internal standard (10). Liver glycogen was determined by a Glycogen Assay Kit (Sigma-Aldrich, 
USA) according to manufacturer’s instructions. Blood gases (pH, HCO3, PCO2) were tested by i-
STAT handheld blood analyzer with the EC8+ cartridges (Abbott, US) (18). 
In vivo VLDL-TG secretion 
Mice were fasted overnight and then injected intraperitoneally (I.P.) with Poloxamer 407 (1  g/kg 
body weight). Blood was collected before and 1, 2, and 3  hours after injection. TG concentration 
was determined by a kit assay (Roche Diagnostics GmbH, Germany). 
Immunoblot analyses 
Livers were homogenized in sucrose buffer (250 mM sucrose, 50 mM Tris, 1 mM EDTA, pH 
7.4), separated by SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) 
membranes (catalog # IPVH00010, Millipore). Antibodies used in this study include anti-adipose 
triglyceride lipase (ATGL) (catalog # 2138, Cell Signaling, USA), anti-fatty acid synthase (FAS) 
(catalog # 3180, Cell Signaling), anti-stearoyl-CoA desaturase 1 (SCD1) (catalog # 2794, Cell 
Signaling), anti-perilipin 2 (Plin2) (catalog # LS-B7983, LifeSpan BioSciences, USA), anti-
perilipin 5 (PLIN5) (catalog # GP31, PROGEN, Germany), anti-α/β hydrolase domain 
5/comparative gene identification-58 (ABHD5/CGI-58) (catalog # 12201-1-AP, Proteintech, 
USA), anti-adipose triglyceride lipase (ATGL) (catalog # 2138, Cell Signaling, USA), anti-cell 
death-induced DFF45-like effector B (CIDEB) (a gift from Dr. Peng Li, Tsinghua University, 
China), anti-phospho-AMP-activated protein kinase (pAMPK) and AMPK (catalog #’s 2531 and 
2532, respectively, Cell Signaling), anti-phospho-ACC (pACC) and ACC (catalog #’s 3661 and 
3662, respectively, Cell Signaling), anti-phospho-HSL (pHSL) and HSL (catalog #’s 4126 and 
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visualized by G:BOX system (SynGene, UK). The relative intensities of resulting bands on the 
blots were analyzed by densitometry using GeneTools program (SynGene). 
RNA isolation and real-time qPCR analysis 
Total liver RNA was isolated using Trizol reagent (Invitrogen, USA). First-strand cDNA was 
synthesized from 2 µg total RNA using Superscript ΙΙΙ reverse transcriptase (Invitrogen) primed 
by oligo (dt)12-18 (Invitrogen) and random primers (Invitrogen). Real-time qPCR was performed 
with Power SYBR® Green PCR Master Mix kit (Life Technologies, UK) using the StepOnePlus-
Real time PCR System (Applied Biosystems, Canada). Data were analyzed with the StepOne 
software (Applied Biosystems). Standard curves were used to calculate mRNA abundance 
relative to that of a control gene, cyclophilin. Real-time qPCR primers are summarized in the 
supplemental Table S2. All primers were synthesized by Integrated DNA Technologies (Canada). 
In vivo lipogenesis 
In vivo lipogenesis with acetate as precursor substrate was performed as described before with 
some modifications (19). In brief, mice fed HSD for 8 weeks were fasted overnight before re-
feeding for 6 hours,, then 30 µCi of 14C-acetate was I.P. injected into each mouse. Liver and 
white adipose tissue (WAT) were harvested 1 h after injection. For liver lipid analysis, lipids were 
exacted from tissues, separated on thin layer chromatography (TLC) plates with hexane:isopropyl 
ether:acetic acid (15:10:1, v/v/v), visualized by exposure to iodine. Radioactivity in the resolved 
lipid classes was determined by scintillation counting. For the WAT, radioactivity was measured 
in the total lipid extracts by scintillation counting. 
Glucose tolerance test 
Mice were fasted for 16 hours prior to oral gavage of glucose (2 g/kg). Plasma levels of glucose 
were monitored at the indicated time points using glucose strips (Accu-Check glucometer, Roche 
Diagnostics, Vienna, Austria). 
Statistics 
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determined by unpaired 2-tailed t test. Data from studies in WT and Ces1d−/− mice fed on chow 
diet and HSD were analyzed by two-way ANOVA followed by Bonferroni post-test (GraphPad 




Effects of Ces1d deficiency on whole body metabolism in mice fed high sucrose diet 
Sixteen weeks old Ces1d-/- and WT mice were fed with HSD or standard chow diet for 8 weeks. 
WT mice did not show difference in body weight between chow and HSD feeding conditions 
(Figure 1A). Although Ces1d-/- mice trended towards a heavier body weight at the beginning of 
the diet-feeding period (Figure 1A), during the 8 weeks feeding the body weight increment was 
blunted in Ces1d-/- mice on both chow diet and HSD. After 8 weeks of feeding no difference in 
body weight was observed between Ces1d deficient and WT mice on either diet (Figure 1A). 
Weight gain curve before the initiation of dietary intervention suggests that Ces1d-/- mice fed a 
regular chow diet reach adult body weight earlier than WT mice during the life phase as mature 
adults (supplemental Figure S1A). Ces1d-/- mice fed HSD tended to lose weight compared with 
the Ces1d-/- mice fed a regular chow diet (Figure 1A). Ces1d-/- mice had less epididymal WAT 
weight and/or lower WAT/body weight ratio on both chow diet and HSD (Figure 1B). MRI scans 
showed no difference in body composition of fat and lean mass percentage in WT and Ces1d-/- 
mice before HSD feeding. HSD feeding increased body fat percentage and decreased lean 
percentage in the WT mice, but this change was not observed in Ces1d-/- mice (supplemental 
Figure S1B and S1C). These data suggest that the lower weight gain observed in the Ces1d-/- mice 
could be at least partially derived from decreased WAT depots compared to WT mice. 
The 16-hour fasting FFA concentration in Ces1d-/- mice either decreased (chow diet) or did not 
change (HSD) compared with WT control groups (Figure 1C). Ces1d-/- mice in the HSD group 
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decreased Ces1d-catalyzed basal lipolysis in Ces1d-/- adipocytes (10, 11). Collectively, these data 
suggest that the decreased fat depot in Ces1d-/- mice fed HSD is not due to increased lipolysis in 
adipose tissue. Consistent with this observation, plasma ketone body concentration was decreased 
in the Ces1d-/- mice on both diets (Figure 1D), reflecting decreased FA utilization. Blood pH, acid 
and gases were also monitored in this study and no difference was observed between genotypes in 
either diet condition (Figure 1E), which confirms that the acid-base balance in the blood was not 
affected neither by the diets nor by the genotype. 
Ces1d-/- mice consumed more chow diet than WT mice during the dark phase but no significant 
differences were observed in HSD intake between WT and Ces1d-/- mice (supplemental Figure 
S2). As expected, the respiratory exchange ratio (RER) values were elevated in both Ces1d-/- and 
WT mice after HSD feeding (Figure 1F), reflecting an increased utilization of carbohydrates as 
the energy source. Ces1d-/- mice showed increased RER values when fed both the chow diet or 
HSD compared to the WT control groups (Figure 1F), indicating more reliance on carbohydrate 
over fat as energy source. There was no difference in energy expenditure between Ces1d-/- and 
WT mice after HSD feeding (data not shown). 
Amelioration of HSD-induced liver lipid accumulation in Ces1d deficient mice  
To determine if Ces1d deficiency can protect against steatosis induced by DNL, analyses were 
performed on livers collected after refeeding when DNL is activated. HSD feeding increased liver 
weight in WT mice but not in Ces1d-/- mice (Figure 2A). As expected, HSD induced an increment 
in hepatic TG content in WT mice; however, HSD had no effect on hepatic TG content in Ces1d-/- 
mice with TG concentrations not differing from chow-fed Ces1d-/- mice (Figure 2B). HSD feeding 
also increased liver cholesteryl ester (CE) and free cholesterol (FC) concentrations in both WT 
and Ces1d-/- mice (Figure 2C and D). Liver FC concentration in HSD-fed Ces1d-/- mice was 
slightly, but significantly decreased compared to WT mice (Figure 2D).  
Considering that the HSD utilized in this study was a fat-free diet, which could potentially lead to 
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determined. After 8 weeks of HSD feeding, both WT and Ces1d-/- mice showed similar decrease 
in hepatic concentration of linoleic acid and α-linolenic acid, and their long-chain metabolites	  
arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid (supplemental Figure S3 A-
E), Oleic acid that can be synthesized in the liver, was increased by HSD feeding in both 
genotypes, although the increment in Ces1d-/- mice was significantly lower in WT mice 
(supplemental Figure S3 F), which is consistent with the obtained liver lipid profiles (Figure 2B) 
and may be the consequence of attenuated TG synthesis. 
HSD feeding slightly increased hepatic mRNA expression of pro-inflammatory genes F4/80 and 
Cd68, but no differences were found between WT and Ces1d-/- mice (supplemental Figure S4).  
No difference was observed in plasma TG concentration between WT and Ces1d-/- mice fed HSD 
(Figure 2E). VLDL-TG secretion rate was not altered in the four groups of animals (supplemental 
Figure S5), suggesting that the difference in the liver lipid profile was not caused by altered 
VLDL secretion.  
Ces1d deficiency regulates liver lipid metabolism through a posttranscriptional mechanism 
Carbohydrate response element binding protein (ChREBP) is activated by carbohydrate 
metabolites leading to up-regulated transcription of genes encoding lipogenic enzymes and 
consequently increased DNL in the liver (6). Two ChREBP isoforms, ChREBP-α and ChREBP-β 
have been characterized. A two-step model has been proposed for ChREBP activation, by which 
carbohydrate-mediated activation of ChREBP-α induces expression of the ChREBP-β isoform 
(20). In the current study, HSD feeding dramatically increased hepatic expression of Mlxipl (beta) 
encoding the ChREBP-β isoform in both WT and Ces1d-/- mice at a comparable level (Figure 3A 
and B). Consequently, hepatic expression of ChREBP target genes Pklr (encoding liver pyruvate 
kinase) and Txnip (encoding thioredoxin-interacting protein) was induced in HSD-fed mice with 
no difference observed between WT and Ces1d-/- mice (Figure 3C and D). These results suggest 
that ablation of Ces1d expression does not affect the regulation of lipogenic gene expression by 
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Liver X receptor (LXR) increases transcription of lipogenic genes by activating sterol regulatory 
element-binding protein-1c (SREBP1c), another important regulatary transcription factor of DNL 
(21). Glucose and its derivatives were demonstrated to induce LXR transcriptional activity (22, 
23). In the present study the expression of Nr1h3 gene encoding LXRα was not changed by 
genotype or diet type (Figure 3E), while the LXRα target gene Abca1 was slightly induced by 
HSD feeding (Figure 3F), suggesting activation of LXR by over-consumption of sugar. 
Expression of LXRα target gene Abca1 was comparable between WT and Ces1d-/- mice on both 
types of diet, which suggests that the attenuated liver lipid accumulation in Ces1d-/- mice was not 
due to changes in LXR-mediated transcriptional activity. 
Consistent with previous studies (24, 25), high-carbohydrate diet elevated expression of Srebf1 in 
the liver of WT and Ces1d-/- mice (Figure 3G). Compared with WT mice, Ces1d-/- mice presented 
with attenuated Srebf1 expression in the liver. However, the SREBP1c target lipogenic enzymes 
FAS and SCD1 did not exhibit different protein abundance between WT and Ces1d-/- groups 
(Figure 4A and B).  Expression of another key enzyme of lipogenesis, ACC was induced by HSD 
feeding to a comparable level in both WT and Ces1d-/- mice (Figure 4C). However, 
phosphorylation state of ACC (p-ACC) was significantly higher in Ces1d-/- mice  compared to the 
WT groups in both diet conditions, suggesting suppressed liver ACC activity in Ces1d-/- mice 
(Figure 4C), which may contribute to the attenuated liver TG accumulation after HSD feeding. It 
is well established that AMPK catalyzes ACC phosphorylation, thereby inhibiting ACC activity 
and DNL (26, 27). In agreement with this canonical regulation, increased phosphorylated state of 
AMPK (p-AMPK) in the livers of Ces1d-/- mice suggests higher AMPK activity (Figure 4D). 
HSD feeding also increased the abundance of SCD1 and ACC but not FAS in the WAT. No 
difference was found between WT and Ces1d-/- mice (supplemental Figure S6A and B). 
Furthermore, P-ACC/ACC and P-AMPK/AMPK ratios also did not change in WAT between WT 
and Ces1d-/- mice (supplemental Figure S6B), suggesting that the effect of Ces1d deficiency on 
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DNL was further assessed by incorporation of [14C]-labeled acetate into lipids in HSD-fed WT 
and Ces1d-/- mice in the refed state. No difference was observed in the incorporation of the 
radioisotope into TG, CE and cholesterol in the liver (supplemental Figure S7), suggesting that 
lipids synthesized from acetate-derived substrate in the liver are comparable between HSD fed 
WT and Ces1d-/- mice. The incorporation of acetate into total lipids in WAT also did not vary 
between HSD-fed WT and Ces1d-/- mice (supplemental Figure S6C). 
Hepatic expression of FA oxidation related genes Cpt1a (encoding carnitine palmitoyltransferase 
1A) and Acox (encoding acyl-CoA oxidase) did not differ between genotypes or diet types after 
fasting (Figure 5A). To investigate whether the attenuated TG accumulation in the liver of Ces1d-
/- mice could be attributed to changes in LD-associated lipase abundance/activity, hepatic 
expression of ATGL and its regulators was assessed. The mRNA expression of G0s2, encoding 
an inhibitor of ATGL (28), was decreased in livers of Ces1d-/- mice fed chow diet when compared 
with the WT group on the same diet, however, no significant difference was seen between the two 
HSD fed groups (Figure 5B). It has been demonstrated that LD coat proteins perilipin 2 (PLIN2) 
and perilipin 5 (PLIN5) block ATGL-mediated lipolysis in the liver (29, 30). PLIN2 and PLIN5 
abundance did not differ between the genotypes (Figure 5C).  Abundance of ATGL coactivator 
ABHD5/CGI-58 also did not differ between WT and Ces1d-/- mice fed either chow diet or HSD 
(Figure 5C). Similar protein abundance of ATGL was found between WT and Ces1d-/- groups 
(Figure 5D).  Hormone sensitive lipase (HSL) is also involved in liver lipolysis (31) and its 
activity is elevated by phosphorylation through PKA pathway and inhibited by dephosphorylation 
through insulin signaling (32). The phosphorylation state of liver HSL did not differ between 
HSD fed WT and Ces1d-/- mice (supplemental Figure S8). These results suggest that the 
attenuation of HSD-induced liver TG accumulation observed in Ces1d-/- mice was independent of 
cytosolic lipase activity in the liver.  
Additional regulators of LD dynamics were investigated. The CIDE protein family, including 
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LD growth (33). Among the three isoforms, CIDEB is prominently expressed in the liver and 
intestine (33). CIDEB knockout mice exhibit resistance to high-fat diet induced steatosis (34). 
The expression of CIDEA and CIDEC is more abundant in the adipose tissue, while their hepatic 
expression is induced in fatty liver and positively correlates with the severity of liver steatosis 
(33, 35, 36). Cidea and Cidec expression levels were variable with Cidea trending towards an 
increase in livers of HSD fed WT but not Ces1d-/- mice (Figure 5E), which could be the result of 
HSD feeding only inducing mild lipid accumulation in the liver (Figure 2B). Cideb expression 
was slightly but significantly induced by HSD in WT mice, whereas Cideb expression in HSD fed 
Ces1d-/- mice was reduced compared to WT mice and did not statistically differ from chow-fed 
WT and Ces1d-/- mice (Figure 5E). Similar protein expression pattern of liver CIDEB among 
groups was observed by immunoblotting (Figure 5D). 
Fibroblast growth factor 21 (FGF21), an endocrine hormone produced by liver, plays an 
important role in the maintenance of lipid and energy homeostasis. Previous studies have 
demonstrated that hepatic FGF21 expression increases in response to HSD or sucrose challenge 
(37, 38). HSD elevated expression of Fgf21 in livers of both WT and Ces1d-/- mice with 
comparable levels (Figure 5F), suggesting the changes in energy and lipid metabolism observed 
in Ces1d-/- mice were not due to regulation by FGF21.  
Glucose metabolism in Ces1d deficient mice fed HSD 
Hepatic mRNA expression of key enzymes in gluconeogenesis has been determined. Decreased 
expression of glucose-6-phosphatase (G6pc) was found in Ces1d-/- mice fed HSD when compared 
to the WT control (Figure 6A). No alterations were observed in the expression of 
phosphoenolpyruvate carboxykinase (Pck1) between genotypes fed either diet (Figure 6A).  
No difference in glucose tolerance was detected between WT and Ces1d-/- mice regardless of diet 
in the oral glucose tolerance test (OGTT) (Figure 6B). No significant difference was found in 
plasma insulin levels after refeeding between genotypes (Figure 6C). These data suggest that the 
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Slightly increased hepatic glycogen concentration was observed in Ces1d-/- mice fed chow diet 
when compared to WT control mice, but no difference was observed between the two HSD fed 
groups (Figure 6D), suggesting that the attenuation of HSD-induced liver TG accumulation in 




The prevalence of NAFLD in humans has increased with the rapid rise in carbohydrate 
consumption (39). The major finding in this study is that Ces1d deficiency prevents HSD-induced 
liver lipid accumulation in vivo.  
DNL is one of the major sources of liver FA. NAFLD patients present with elevated hepatic 
DNL, which contributes to hepatic lipid accumulation (40). It is well documented that over-
consumption of a high-carbohydrate diet, in particular simple sugars such as fructose and sucrose, 
dramatically induces hepatic DNL (41, 42) mainly through over-activation of lipogenesis master 
regulators ChREBP (6, 20) and SREBP1c (24, 25) and providing excess substrate for lipogenesis. 
In the present study, mice lacking Ces1d were protected from HSD feeding-induced liver TG 
accumulation. This occurred despite activation of both the ChREBP and SREBP1c pathways to a 
comparable level by HSD feeding in Ces1d deficient and WT control groups, suggesting that the 
attenuated hepatic TG accumulation observed in the Ces1d deficient mice was due to an 
alternative mechanism. Activities of a number of lipogenic enzymes are regulated by post-
transcriptional mechanisms. AMPK has emerged as a key regulator of energy balance and plays 
an important role in regulating lipid and carbohydrate homeostasis. It has been well established 
that AMPK suppresses lipid synthesis through phosphorylation of key enzymes in FA and 
cholesterol biosynthesis pathways (26, 27, 43, 44). Activation of AMPK inhibits FA synthesis by 
phosphorylating ACC1 at Ser79 (45). Liver-specific activation of AMPK has been shown to 
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AMPK activation and ACC1 phosphorylation were observed in Ces1d deficient mice fed HSD. 
The mechanism by which AMPK is activated in livers of Ces1d−/− mice and how it is related to 
the changes in whole body metabolism (such as decreased fat deposition and increased RER) 
remains to be determined. 
Despite decreased hepatic lipid concentration in HSD fed Ces1d−/− mice compared to WT mice, 
the abundance of LD-coat protein PLIN2 was not significantly different. It has been reported that 
AMPK catalyzes phosphorylation of PLIN2 thereby facilitates association of ATGL to LDs to 
catalyze lipolysis (47). This mechanism would be consistent with the observed increase in AMPK 
activation in livers of Ces1d−/− mice.  
Ces1d and its human ortholog CES1 have been shown to play a role in the regulation of lipid 
metabolism (48). Ces1d participates in basal lipolysis in adipocytes (10, 11) and in the provision 
of substrates for the assembly of hepatic VLDL (8). The absence of Ces1d decreases VLDL 
secretion in vivo but does not cause liver steatosis (49), which may be at least partially 
attributable to decreased FA flux from adipose tissue to the liver in Ces1d knockout mice (49). 
Additionally, increased FA oxidation was observed in the Ces1d deficient hepatocytes and liver-
specific Ces1d knockout mice (49, 50), which could also contribute to the prevention of liver lipid 
accumulation. We demonstrated in our previous study that ablation of Ces1d expression protects 
mice from high-fat diet-induced liver steatosis by decreasing hepatic DNL, increasing FA 
oxidation, and enhancing insulin sensitivity (16). Unlike our observations in the HSD fed Ces1d 
knockout mice, reduction of lipogenesis in Ces1d−/− mice after high-fat diet feeding was 
attributable to reduced expression of SREBP1c target enzymes including SCD1 and ACC instead 
of post-transcriptional regulation of the enzyme activity. The distinct mechanisms observed 
between the two studies could be explained by the different diets used. In the present study, 
although Srebf1 mRNA abundance was decreased in the HSD fed Ces1d−/− mice, this change did 
not diminish the expression of target enzymes, which is likely due to the compensatory over-













	   15	  
Increased liver FA oxidation was observed in the high-fat diet fed Ces1d deficient mice compared 
with the WT control mice fed the same diet (16). In the high-sucrose, fat-free diet- fed Ces1d-/- 
mice, we did not observe enhanced levels of plasma ketone body concentration and expression of 
genes involved in FA oxidation in the liver in fasted state, which may be due to decreased FA 
flux to the liver and a shift towards carbohydrate as the primary energy source identified by the 
increased RER. Increased utilization of carbohydrates as the energy source in HSD feeding 
condition may also decrease the availability of substrates derived from carbohydrates for DNL in 
the liver of Ces1d-/- mice, thus contributing to attenuated lipid synthesis. On the other hand, the 
decreased FA flux in the circulation may also contribute to reduced lipid storage in the livers of 
HSD fed Ces1d-/- mice. 
Decreased plasma TG was observed in chow fed Ces1d-/- mice compared to WT mice under fasted 
state despite unchanged rate of VLDL-TG secretion. This is consistent with previous observations 
in Ces1d-/- mice fed chow diet suggesting compensatory TG association with apoB48-containing 
lipoproteins (49, 51). In the current study, HSD feeding decreased plasma TG but did not affect 
VLDL secretion rate, and no difference was observed between Ces1d-/- and WT mice, suggesting 
that the difference in liver lipid storage among animal groups was unlikely due to changes in 
VLDL assembly. 
In vivo lipogenesis experiments using labeled acetate as the lipogenic substrate did not show 
differences in HSD fed WT and Ces1d-/- mice during the refed state, when lipogenesis is most 
active. However, this result only demonstrates that lipid synthesis from acetate-derived substrate 
was not changed by Ces1d deficiency. HSD feeding increases acetyl-CoA flux from carbohydrate 
metabolism to lipogenesis (52). The RER data showed increased carbohydrate utilization in 
Ces1d-/- mice over FA, which could result in different cytosolic acetyl-CoA pools between HSD 
fed WT and Ces1d-/- mice and lead to reduced dilution by endogenous acetyl-CoA and increased 
acetyl-CoA specific radioactivity in Ces1d-/- mice. Future studies should consider using other 
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In conclusion, HSD over-consumption leads to significantly enhanced DNL and lipid 
accumulation in the liver. Emerging evidence from recent epidemiological and biochemical 
studies suggest that high dietary intake of carbohydrate is an important causative factor in the 
development of metabolic syndrome features including NAFLD. Our data suggest that ablation of 
Ces1d activity reduces hepatic lipid accumulation, and therefore inhibition of the human ortholog 
CES1 might represent a novel pharmacological target for prevention and treatment of NAFLD.  
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Figure 1. Effects of HSD and Ces1d deficiency on whole body metabolism. (A) Body weight of WT and 
Ces1d-/- mice fed either chow or HSD for 8 weeks. N=6, values are mean ± SEM. *P<0.05, **P<0.01, 
***P<0.001 vs WT group on the same diet condition, #P  <  0.05, ##P  <  0.01, ###P  <  0.001  vs HSD fed group 
in the same genotype. (B) Epididymal white adipose tissue (WAT) weight and WAT/body weight ratio of 
WT and Ces1d-/- mice fed either chow or HSD for 8 weeks. (C) Plasma free fatty acid concentrations in 
fasted and refed WT and Ces1d-/- mice fed either chow or HSD for 8 weeks. (D) Fasted plasma ketone body 
concentration in WT and Ces1d-/- mice fed either chow or HSD for 8 weeks. (E) Blood acid-base 
measurements after fasting in WT and Ces1d-/- mice fed either chow diet or HSD for 8 weeks. N=6-7, 
values are mean ± SEM. *P<0.05, ***P<0.001. (F) Respiratory exchange ratio (RER) of WT and Ces1d-/- 
mice fed either chow or HSD. N=6. *P<0.05, **P<0.01, ***P<0.001 for significance between groups in 























































































































Figure 2. Ces1d deficiency ameliorated HSD-induced liver lipid accumulation. (A) Liver and body 
weight ratio of WT and Ces1d-/- mice fed either chow or HSD for 8 weeks. (B) Liver TG, (C) CE, and (D) 
FC concentrations in WT and Ces1d-/- mice fed either chow or HSD for 8 weeks. (E) Plasma TG 
concentrations in WT and Ces1d-/- mice fed either chow or HSD for 8 weeks. N=6, values are mean ± SEM. 












































































































































































































Figure 3. Effects of HSD and Ces1d deficiency on hepatic expression of lipogenic and lipid efflux 
regulatory genes. Hepatic mRNA expression of (A) Mlxipl (alpha), (B) Mlxipl (beta), ChREBP targets (C) 
Pklr and (D) Txnip, (E) Nrlh3 and (F) LXRα target Abca1, and (G) Srebf1c in WT and Ces1d-/- mice fed 
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Figure 4. Effects of HSD and Ces1d deficiency on regulatory hepatic lipogenic enzymes and AMPK. 
Abundance of liver (A) FAS, (B) SCD-1, (C) p-ACC/ACC, and (D) p-AMPK/AMPK in chow or HSD fed 
WT and Ces1d−/− mice was assessed by immunoblotting. Values of relative band intensities were shown as 














































































































































































































































































Figure 5. Effects of HSD and Ces1d deficiency on regulatory hepatic lipid droplet metabolic genes/
enzymes. (A) Hepatic mRNA expression of genes involved in FA oxidation in fasted WT and Ces1d-/- mice 
(n=6). (B) Hepatic mRNA expression of ATGL inhibitor G0s2 (n=6). (C) Protein abundance of perilipin 2 
(PLIN2), perilipin 5 (PLIN5), and ATGL coactivator CGI-58 in the liver of WT and Ces1d-/- mice was 
assessed by immunoblotting. (D) Protein abundance of ATGL and lipid droplet (LD)-associated protein 
CIDEB in the liver of WT and Ces1d-/- mice was assessed by immunoblotting. (E) Hepatic mRNA 
expression of LD-associated proteins CIDEA, CIDEB, and CIDEC (n=6). (F) Hepatic mRNA expression of 
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Figure 6. Effects of HSD and Ces1d deficiency on glucose metabolism. (A) Hepatic mRNA expression 
of key enzymes of gluconeogenesis in WT and Ces1d-/- mice (n=6). (B) Glucose tolerance test (OGTT) in 
WT and Ces1d-/- mice fed either chow or HSD (n=5-8). (C) Plasma insulin concentration after refeeding in 
WT and Ces1d-/- mice fed either chow or HSD for 8 weeks (n=6). (D) Liver glycogen after refeeding in WT 
and Ces1d-/- mice fed either chow or HSD for 8 weeks (n=6). Values are mean ± SEM. *P<0.05, **P<0.01, 
***P<0.001. 
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